Sign in
Not yet recruitingPhase 2

Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence

Key facts

Who runs it
University Hospital, Tours
Where
France1 site in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
34 people, planned
Started
1 Sept 2026
Expected to end
1 Mar 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Propranolol, 120mg
  • Placebo
Record updated
5 March 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • female, cisgender
  • >= 18 years
  • The patient agrees to comply with the contraception requirements detailed in the protocol
  • SBP > 10 cmHg
  • Heart rate >= 55 bpm
  • Received for consultation regarding sexual violence at the Medical-Legal Unit (UMJ) for sexual assault and/or rape within 72 hours of the incident occurring
  • Affiliated with a social security system
  • Patient who understands and reads french
  • Free, informed, and written consent signed by the participant

Who cannot take part

  • Current use of a drug that has a contraindicated or inadvisable drug interaction with propranolol: bepridil, diltiazem, verapamil, fingolimod
  • Current treatment with benzodiazepines
  • Individuals currently receiving psychotropic treatment such as antipsychotics or antidepressants
  • High suicide risk, i.e., participants who responded positively to items 4 or 5 of the C-SSRS suicidal ideation scale or any positive assessment of suicidal behavior in the 6 months prior to selection
  • Patients who have previously been diagnosed with PTSD
  • Known hypersensitivity to propranolol or treated asthma, even if only occasional
  • Patient with myasthenia gravis, with a personal history of psoriasis
  • Patient with severe liver disease and/or significant renal impairment
  • Addiction: presence of a current disorder related to the use of psychoactive substances
  • People with known current or past serious psychiatric disorders
  • Protected adult (guardianship, curatorship, judicial protection)
  • Repeated or chronic sexual violence
  • Impaired consciousness or alertness, amnesia regarding events
  • Known interactions with Propranolol (combinations not recommended and combinations to be used with caution) indicated in the summary of product characteristics
  • Patients who have suffered head trauma within the last year or who have clinical symptoms and neurological sequelae
  • Patient wearing contact lenses
  • Current use of a beta-blocker, regardless of dosage form
  • Pregnant or breastfeeding women

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the effect of early propranolol administration on the occurrence of post-traumatic stress disorder (PTSD) symptoms at five weeks in adult female victims of sexual violence.

Read full original descriptionShow less

The investigators hypothesize that propranolol administration may reduce the traumatic emotional experience associated with the memory by positively modulating neurovegetative symptoms during the memory reconsolidation phase, thereby decreasing the risk of developing post-traumatic stress disorder (PTSD). This specific context of sexual violence appears particularly suitable, given the timeline of events, to evaluate the pharmacological efficacy of propranolol on memory reconsolidation and the prevention of post-traumatic symptom development.

Participants will :

* take Propranolol, 120mg per day divided into 3 daily doses of 40mg or a placebo for 10 days, followed by a tapering phase consisting of two daily doses of 40 mg for 7 days, and then a single daily dose of 40 mg for an additional 7 days. * Complete questionnaires * Complete a patient follow-up diary documenting information related to the occurrence of adverse events.

The 2 groups in the trial

  • Propranolol, 120mgTreatment being tested
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence: A Single-Center Randomized Placebo-Controlled Pilot Study
Record updated
5 March 2026